These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

930 related articles for article (PubMed ID: 9337215)

  • 1. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: I. Effects on left ventricular performance and neurohormonal systems.
    Spinale FG; de Gasparo M; Whitebread S; Hebbar L; Clair MJ; Melton DM; Krombach RS; Mukherjee R; Iannini JP; O SJ
    Circulation; 1997 Oct; 96(7):2385-96. PubMed ID: 9337215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: II. Effects on myocyte contractile processes.
    Spinale FG; Mukherjee R; Iannini JP; Whitebread S; Hebbar L; Clair MJ; Melton DM; Cox MH; Thomas PB; de Gasparo M
    Circulation; 1997 Oct; 96(7):2397-406. PubMed ID: 9337216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin converting enzyme inhibition, AT1 receptor inhibition, and combination therapy with pacing induced heart failure: effects on left ventricular performance and regional blood flow patterns.
    Krombach RS; Clair MJ; Hendrick JW; Houck WV; Zellner JL; Kribbs SB; Whitebread S; Mukherjee R; de Gasparo M; Spinale FG
    Cardiovasc Res; 1998 Jun; 38(3):631-45. PubMed ID: 9747431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AT1 angiotensin II receptor inhibition in pacing-induced heart failure: effects on left ventricular performance and regional blood flow patterns.
    Clair MJ; Krombach RS; Hendrick JW; Houck WV; Hebbar L; Kribbs SB; Rios G; Whitebread S; Mukherjee R; de Gasparo M; Spinale FG
    J Card Fail; 1998 Dec; 4(4):311-23. PubMed ID: 9924853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin AT1 receptor inhibition, angiotensin-converting enzyme inhibition, and combination therapy with developing heart failure: cellular mechanisms of action.
    Spinale FG; Iannini JP; Mukherjee R; Melton DM; de Gasparo M
    J Card Fail; 1998 Dec; 4(4):325-32. PubMed ID: 9924854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of combined angiotensin II and endothelin receptor blockade with developing heart failure: effects on left ventricular performance.
    New RB; Sampson AC; King MK; Hendrick JW; Clair MJ; McElmurray JH; Mandel J; Mukherjee R; de Gasparo M; Spinale FG
    Circulation; 2000 Sep; 102(12):1447-53. PubMed ID: 10993866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin II subtype-1 receptor blockade during the development of left ventricular hypertrophy in dogs: effects on ventricular and myocyte function.
    Spinale FG; Holzgrefe HH; Walker JD; Mukherjee R; Kribbs SB; Powell JR; Antonaccio M
    J Cardiovasc Pharmacol; 1997 Nov; 30(5):623-31. PubMed ID: 9388045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin-converting enzyme inhibition and angiotensin II subtype-1 receptor blockade during the progression of left ventricular dysfunction: differential effects on myocyte contractile processes.
    Spinale FG; Holzgrefe HH; Mukherjee R; Webb ML; Hird RB; Cavallo MJ; Powell JR; Koster WH
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1082-94. PubMed ID: 9399980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin AT1 receptor inhibition in pacing induced heart failure: effects on left ventricular myocardial collagen content and composition.
    Clair MJ; Krombach RS; Coker ML; Heslin TL; Kribbs SB; de Gasparo M; Spinale FG
    J Mol Cell Cardiol; 1998 Nov; 30(11):2355-64. PubMed ID: 9925371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myocardial bradykinin following acute angiotensin-converting enzyme inhibition, AT1 receptor blockade, or combined inhibition in congestive heart failure.
    Multani MM; Krombach RS; Goldberg AT; King MK; Hendrick JW; Sample JA; Baicu SC; Joffs C; deGasparo M; Spinale FG
    J Cardiovasc Pharmacol Ther; 2001 Oct; 6(4):369-76. PubMed ID: 11907639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amlodipine monotherapy, angiotensin-converting enzyme inhibition, and combination therapy with pacing-induced heart failure.
    Kribbs SB; Merritt WM; Clair MJ; Krombach RS; Houck WV; Dodd MG; Mukherjee R; Spinale FG
    Hypertension; 1998 Mar; 31(3):755-65. PubMed ID: 9495258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancing cardiac protection after myocardial infarction: rationale for newer clinical trials of angiotensin receptor blockers.
    Pfeffer MA
    Am Heart J; 2000 Jan; 139(1 Pt 2):S23-8. PubMed ID: 10618584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Angiotensin II receptor blockers: current status and future prospects].
    Corvol P; Plouin PF
    Drugs; 2002; 62 Spec No 1():53-64. PubMed ID: 12036389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term angiotensin-converting enzyme and angiotensin I--receptor inhibition in pacing-induced heart failure: effects on myocardial interstitial bradykinin levels.
    Multani MM; Krombach RS; Hendrick JW; Baicu SC; Joffs C; Sample JA; deGasparo M; Spinale FG
    J Card Fail; 2001 Dec; 7(4):348-54. PubMed ID: 11782859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional role of endogenous endothelin-1 in congestive heart failure treated with angiotensin II receptor antagonist.
    Dohi K; Onishi K; Kitamura T; Okinaka T; Ito M; Isaka N; Nakano T
    Jpn J Physiol; 2001 Aug; 51(4):445-53. PubMed ID: 11564281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renin-angiotensin system inhibition on noradrenergic nerve terminal function in pacing-induced heart failure.
    Kawai H; Stevens SY; Liang CS
    Am J Physiol Heart Circ Physiol; 2000 Dec; 279(6):H3012-9. PubMed ID: 11087259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Combined therapy with quinapril, an ACE inhibitor, and valsartan, a type 1 angiotensin II receptors blocker, for moderate chronic cardiac failure may raise the degree of neurohormonal block and improve 24-h heart rate variability compared to the effect of monotherapy (data from the trial SADKO-CHF)].
    Skvortsov AA; Nasonova SN; Sychev AV; Arbolishvili GN; Baklanova NA; Mareev VIu; Belenkov IuN
    Ter Arkh; 2005; 77(8):34-43. PubMed ID: 16206603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of renal glomerular angiotensin II receptors by ace inhibition and AT1 receptor antagonism.
    Haddad G; Amiri F; Garcia R
    Regul Pept; 1997 Jan; 68(2):111-7. PubMed ID: 9110382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of AT2 receptors in the cardioprotective effect of AT1 antagonists in mice.
    Xu J; Carretero OA; Liu YH; Shesely EG; Yang F; Kapke A; Yang XP
    Hypertension; 2002 Sep; 40(3):244-50. PubMed ID: 12215461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Interplay between the Renin Angiotensin System and Pacing Postconditioning Induced Cardiac Protection.
    Babiker F; Al-Jarallah A; Joseph S
    PLoS One; 2016; 11(11):e0165777. PubMed ID: 27814397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.